MedChemComm最新文献

筛选
英文 中文
Discovery of new 1,3-diphenylurea appended aryl pyridine derivatives as apoptosis inducers through c-MET and VEGFR-2 inhibition: design, synthesis, in vivo and in silico studies† 通过抑制 c-MET 和 VEGFR-2 发现作为细胞凋亡诱导剂的新型 1,3-二苯基脲附加芳基吡啶衍生物:设计、合成、体内和硅学研究
IF 3.597
MedChemComm Pub Date : 2024-06-12 DOI: 10.1039/D4MD00280F
Heba A. Elsebaie, Mohamed S. Nafie, Haytham O. Tawfik, Amany Belal, Mohammed M. Ghoneim, Ahmad J. Obaidullah, Salwa Shaaban, Abdelmoneim A. Ayed, Mohamed El-Naggar, Ahmed B. M. Mehany and Moataz A. Shaldam
{"title":"Discovery of new 1,3-diphenylurea appended aryl pyridine derivatives as apoptosis inducers through c-MET and VEGFR-2 inhibition: design, synthesis, in vivo and in silico studies†","authors":"Heba A. Elsebaie, Mohamed S. Nafie, Haytham O. Tawfik, Amany Belal, Mohammed M. Ghoneim, Ahmad J. Obaidullah, Salwa Shaaban, Abdelmoneim A. Ayed, Mohamed El-Naggar, Ahmed B. M. Mehany and Moataz A. Shaldam","doi":"10.1039/D4MD00280F","DOIUrl":"10.1039/D4MD00280F","url":null,"abstract":"<p >Interest has been generated in VEGFR-2 and c-MET as potential receptors for the treatment of different malignancies. Using aryl pyridine derivatives with 1,3-diphenylurea attached, a number of promising dual VEGFR-2 and c-MET inhibitors were developed and synthesized. Regarding the molecular target, compounds <strong>2d</strong>, <strong>2f</strong>, <strong>2j</strong>, <strong>2k</strong>, and <strong>2n</strong> had potent IC<small><sub>50</sub></small> values of 65, 24, 150, 170, and 18 nM against c-MET, respectively. Additionally, they had potent IC<small><sub>50</sub></small> values of 310, 35, 290, 320, and 24 nM against VEGFR-2, respectively. Regarding cytotoxicity, compounds <strong>2d</strong>, <strong>2f</strong>, <strong>2j</strong>, <strong>2k</strong> and <strong>2n</strong> exhibited potent cytotoxicity against MCF-7 with IC<small><sub>50</sub></small> values in the range 0.76–21.5 μM, and they showed promising cytotoxic activity against PC-3 with IC<small><sub>50</sub></small> values in the range 1.85–3.42 μM compared to cabozantinib (IC<small><sub>50</sub></small> = 1.06 μM against MCF-7 and 2.01 μM against PC-3). Regarding cell death, compound <strong>2n</strong> caused cell death in MCF-7 cells by 87.34-fold; it induced total apoptosis by 33.19% (8.04% for late apoptosis, 25.15% for early apoptosis), stopping their growth in the G<small><sub>2</sub></small>/M phase, affecting the expression of apoptosis-related genes P53, Bax, caspases 3 and 9 and the anti-apoptotic gene, Bcl-2. <em>In vivo</em> study illustrated the anticancer activity of compound <strong>2n</strong> by reduction of tumor mass and volume, and the tumor inhibition ratio reached 56.1% with an improvement of hematological parameters. Accordingly, compound <strong>2n</strong> can be further developed as a selective target-oriented chemotherapeutic against breast cancer.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2553-2569"},"PeriodicalIF":3.597,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
N-Sulfonylphenoxazines as neuronal calcium ion channel blockers† 作为神经元钙离子通道阻滞剂的 N-磺酰吩噁嗪类化合物
IF 3.597
MedChemComm Pub Date : 2024-06-12 DOI: 10.1039/D4MD00336E
Matthieu Schmit, Md. Mahadhi Hasan, Yashad Dongol, Fernanda C. Cardoso, Michael J. Kuiper, Richard J. Lewis, Peter J. Duggan and Kellie L. Tuck
{"title":"N-Sulfonylphenoxazines as neuronal calcium ion channel blockers†","authors":"Matthieu Schmit, Md. Mahadhi Hasan, Yashad Dongol, Fernanda C. Cardoso, Michael J. Kuiper, Richard J. Lewis, Peter J. Duggan and Kellie L. Tuck","doi":"10.1039/D4MD00336E","DOIUrl":"10.1039/D4MD00336E","url":null,"abstract":"<p >Neuropathic pain is a type of chronic pain, usually caused by nerve damage, that responds poorly to traditional pain therapies. The N-type calcium channel (Ca<small><sub>V</sub></small>2.2) is a well-validated pharmacological target to treat this condition. In order to further improve the inhibition of the N-type calcium channel relative to previously described inhibitors, and also address their problematic instability in blood plasma, the development of <em>N</em>-sulfonylphenoxazines as new calcium channel inhibitors was pursued. A series of <em>N</em>-sulfonylphenoxazines bearing ammonium side chains were synthesised and tested for their ability to inhibit both Ca<small><sub>V</sub></small>2.2 and Ca<small><sub>V</sub></small>3.2 (T-type) neuronal ion channels. Compounds with low micromolar activity in Ca<small><sub>V</sub></small>2.2 were identified, equivalent to the most effective reported for this class of bioactive, and calculations based on their physical and chemical characteristics suggest that the best performing compounds have a high likelihood of being able to penetrate the blood–brain barrier. Representative <em>N</em>-sulfonylphenoxazines were tested for their stability in rat plasma and were found to be much more resilient than the previously reported <em>N</em>-acyl analogues. These compounds were also found to be relatively stable in an <em>in vitro</em> liver microsome metabolism model, the first time that this has been investigated for this class of compound. Finally, molecular modelling of the Ca<small><sub>V</sub></small>2.2 channel was used to gain an understanding of the mode of action of these inhibitors at a molecular level. They appear to bind in a part of the channel, in and above its selectivity filter, in a way that hinders its ability to undergo the conformational changes required to open and allow calcium ions to pass through.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2400-2412"},"PeriodicalIF":3.597,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00336e?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents 更正:作为广谱抗鼻病毒药物的高效力和选择性磷脂酰肌醇 4- 激酶 IIIβ 抑制剂
IF 3.597
MedChemComm Pub Date : 2024-06-12 DOI: 10.1039/D4MD90022G
Avinash G. Vishakantegowda, Dasom Hwang, Prashant Chakrasali, Eunhye Jung, Joo-Youn Lee, Jin Soo Shin and Young-Sik Jung
{"title":"Correction: Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents","authors":"Avinash G. Vishakantegowda, Dasom Hwang, Prashant Chakrasali, Eunhye Jung, Joo-Youn Lee, Jin Soo Shin and Young-Sik Jung","doi":"10.1039/D4MD90022G","DOIUrl":"https://doi.org/10.1039/D4MD90022G","url":null,"abstract":"<p >Correction for ‘Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents’ by Avinash G. Vishakantegowda <em>et al.</em>, <em>RSC Med. Chem.</em>, 2024, <strong>15</strong>, 704–719, https://doi.org/10.1039/D3MD00630A.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 6","pages":" 2196-2197"},"PeriodicalIF":3.597,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md90022g?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141430135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A method for estimation of plasma protein binding using diffusion ordered NMR spectroscopy (DOSY)† 利用扩散有序核磁共振光谱(DOSY)估算血浆蛋白结合力的方法
IF 3.597
MedChemComm Pub Date : 2024-06-11 DOI: 10.1039/D4MD00244J
Rachel Taylor, Thomas Swift, David Wilkinson and Kamyar Afarinkia
{"title":"A method for estimation of plasma protein binding using diffusion ordered NMR spectroscopy (DOSY)†","authors":"Rachel Taylor, Thomas Swift, David Wilkinson and Kamyar Afarinkia","doi":"10.1039/D4MD00244J","DOIUrl":"10.1039/D4MD00244J","url":null,"abstract":"<p >The plasma protein binding (PPB) of a drug plays a key role in both its pharmacokinetic and pharmacodynamic properties. During lead optimisation, medium and high throughput methods for the early determination of PPB can provide important information about potential PKPD profile within a chemotype or between different chemotype series. Diffusion ordered spectroscopy (DOSY) is an NMR spectroscopic technique that measures the diffusion of a molecule through the magnetic field gradient, according to its molecular size/weight. Here, we describe the use of DOSY for a rapid and straightforward method to evaluate the PPB of drug molecules, using their binding to bovine serum albumin (BSA) as a model.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2372-2379"},"PeriodicalIF":3.597,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New pyrazole–pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, in silico studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages† 作为选择性 COX-2 抑制剂的新型吡唑哒嗪杂化物:设计、合成、分子对接、硅学研究,以及通过评估 TNF-α、IL-6、PGE-2 和 NO 在 LPS 诱导的 RAW264.7 巨噬细胞中的作用来研究其抗炎潜力
IF 3.597
MedChemComm Pub Date : 2024-06-05 DOI: 10.1039/D4MD00135D
Eman O. Osman, Nadia A. Khalil, Alaa Magdy and Yara El-Dash
{"title":"New pyrazole–pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, in silico studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages†","authors":"Eman O. Osman, Nadia A. Khalil, Alaa Magdy and Yara El-Dash","doi":"10.1039/D4MD00135D","DOIUrl":"10.1039/D4MD00135D","url":null,"abstract":"<p >Hybrid-based design has gained significant interest in the development of novel active substances with anti-inflammatory properties. In this study, two series of new pyrazole–pyridazine-based hybrids, <strong>5a–f</strong> and <strong>6a–f</strong>, were designed and synthesized. Molecules containing pyrazole and pyridazine pharmacophores in a single molecule, each with a unique mechanism of action and different pharmacological characteristics, are believed to exert higher biological activity. The cell viability of all compounds was evaluated using MTT assay in LPS-induced RAW264.7 macrophages. <em>In vitro</em> COX-1 and COX-2 inhibition assays were performed for the investigation of the anti-inflammatory activity of target compounds. Trimethoxy derivatives <strong>5f</strong> and <strong>6f</strong> were the most active candidates, demonstrating higher COX-2 inhibitory action than celecoxib, with IC<small><sub>50</sub></small> values of 1.50 and 1.15 μM, respectively. Bromo derivative <strong>6e</strong> demonstrated a COX-2 inhibitory activity comparable to celecoxib. Further, the ability of compounds <strong>5f</strong>, <strong>6e</strong>, and <strong>6f</strong> to inhibit the generation of specific pro-inflammatory cytokines and mediators, including nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and prostaglandin-E2 (PGE-2), in RAW264.7 macrophages stimulated by LPS was also estimated. Compounds <strong>5f</strong> and <strong>6f</strong> demonstrated the most potent activity. Morover, according to the investigation using molecular modeling studies, derivatives <strong>5f</strong> and <strong>6f</strong> showed respectable binding affinity towards the COX-2 active site compared to the reference ligand. Moreover, the ADME parameters, physicochemical characteristics, pharmacokinetic characteristics, and l of the most potent compounds were also computed.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 8","pages":" 2692-2708"},"PeriodicalIF":3.597,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents 作为抗癌剂的铜选择性 8-氨基喹啉基四价螯合剂
IF 3.597
MedChemComm Pub Date : 2024-06-04 DOI: 10.1039/D4MD00171K
Yingzhen Guan, Michel Nguyen, Anne Robert, Yan Liu and Bernard Meunier
{"title":"Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents","authors":"Yingzhen Guan, Michel Nguyen, Anne Robert, Yan Liu and Bernard Meunier","doi":"10.1039/D4MD00171K","DOIUrl":"10.1039/D4MD00171K","url":null,"abstract":"<p >Cancer cell proliferation and metastasis are known to be dependent on angiogenesis which is regulated by several parameters including copper availability. Tetradentate monoquinoline (TDMQ) ligands constitute a series of chelators tailored to regulate copper homeostasis due to their specificity for copper(<small>II</small>) with respect to Cu(<small>I</small>) or other biometals like iron or zinc. One of these chelators, TDMQ20 efficiently inhibits both proliferation and migration of several human cancer cell lines, better than the reference drug 5-fluorouracil, and with higher selectivity indexes with respect to non-cancer human cells. The biological activity of TDMQ20 may be driven by the coordination chemistry of copper, and the ability of this chelator to restore copper homeostasis and its subsequent redox properties. The anticancer mechanism of action of TDMQ20 involves intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of tumor cell apoptosis. These data support the selection of TDMQ20 as drug-candidate against several human cancers.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 9","pages":" 3048-3056"},"PeriodicalIF":3.597,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00171k?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phosphonodiamidate prodrugs of phosphoantigens (ProPAgens) exhibit potent Vγ9/Vδ2 T cell activation and eradication of cancer cells† 磷酸抗原的膦酰二胺原药(ProPAgens)具有强效的 Vγ9/Vδ2 T 细胞活化和消灭癌细胞的作用
IF 3.597
MedChemComm Pub Date : 2024-06-03 DOI: 10.1039/D4MD00208C
Qin Xu, Maria Sharif, Edward James, Jack O. Dismorr, James H. R. Tucker, Benjamin E. Willcox and Youcef Mehellou
{"title":"Phosphonodiamidate prodrugs of phosphoantigens (ProPAgens) exhibit potent Vγ9/Vδ2 T cell activation and eradication of cancer cells†","authors":"Qin Xu, Maria Sharif, Edward James, Jack O. Dismorr, James H. R. Tucker, Benjamin E. Willcox and Youcef Mehellou","doi":"10.1039/D4MD00208C","DOIUrl":"10.1039/D4MD00208C","url":null,"abstract":"<p >The phosphoantigen (<em>E</em>)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) is an established activator of Vγ9/Vδ2 T cells and stimulates downstream effector functions including cytotoxicity and cytokine production. In order to improve its drug-like properties, we herein report the design, synthesis, serum stability, <em>in vitro</em> metabolism, and biological evaluation of a new class of symmetrical phosphonodiamidate prodrugs of methylene and difluoromethylene monophosphonate derivatives of HMBPP. These prodrugs, termed phosphonodiamidate ProPAgens, were synthesized in good yields, exhibited excellent serum stability (&gt;7 h), and their <em>in vitro</em> metabolism was shown to be initiated by carboxypeptidase Y. These phosphonodiamidate ProPAgens triggered potent activation of Vγ9/Vδ2 T cells, which translated into efficient Vγ9/Vδ2 T cell-mediated eradication of bladder cancer cells <em>in vitro</em>. Together, these findings showcase the potential of these phosphonodiamidate ProPAgens as Vγ9/Vδ2 T cell modulators that could be further developed as novel cancer immunotherapeutic agents.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2462-2473"},"PeriodicalIF":3.597,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00208c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141531763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging bounded datapoints to classify molecular potency improvements† 利用有界数据点对分子效力改进进行分类
IF 3.597
MedChemComm Pub Date : 2024-05-31 DOI: 10.1039/D4MD00325J
Zachary Fralish, Paul Skaluba and Daniel Reker
{"title":"Leveraging bounded datapoints to classify molecular potency improvements†","authors":"Zachary Fralish, Paul Skaluba and Daniel Reker","doi":"10.1039/D4MD00325J","DOIUrl":"10.1039/D4MD00325J","url":null,"abstract":"<p >Molecular machine learning algorithms are becoming increasingly powerful at predicting the potency of potential drug candidates to guide molecular discovery, lead series prioritization, and structural optimization. However, a substantial amount of inhibition data is bounded and inaccessible to traditional regression algorithms. Here, we develop a novel molecular pairing approach to process this data. This creates a new classification task of predicting which one of two paired molecules is more potent. This novel classification task can be accurately solved by various, established molecular machine learning algorithms, including XGBoost and Chemprop. Across 230 ChEMBL IC<small><sub>50</sub></small> datasets, both tree-based and neural network-based “DeltaClassifiers” show improvements over traditional regression approaches in correctly classifying molecular potency improvements. The Chemprop-based deep DeltaClassifier outperformed all here evaluated regression approaches for paired molecules with shared and with distinct scaffolds, highlighting the promise of this approach for molecular optimization and scaffold-hopping.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2474-2482"},"PeriodicalIF":3.597,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00325j?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141190404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of atropisomerism on a non-steroidal glucocorticoid receptor agonist† 阿托品异构对一种非甾体糖皮质激素受体激动剂的影响
IF 3.597
MedChemComm Pub Date : 2024-05-31 DOI: 10.1039/D4MD00245H
Zhou Xu, Zhongyuan Wang, Xiaona Shi, Rui Ding, Li Han, Xueping Yang, Hongmei Zhang and Adrian D. Hobson
{"title":"Impact of atropisomerism on a non-steroidal glucocorticoid receptor agonist†","authors":"Zhou Xu, Zhongyuan Wang, Xiaona Shi, Rui Ding, Li Han, Xueping Yang, Hongmei Zhang and Adrian D. Hobson","doi":"10.1039/D4MD00245H","DOIUrl":"10.1039/D4MD00245H","url":null,"abstract":"<p >To investigate atropisomers of non-steroidal glucocorticoid receptor modulator GSK866, a virtual library of substituted benzoic acid analogues was enumerated. Compounds from this library were subjected to a torsion angle scan using Spartan'20 to calculate the torsion rotation energy barrier which identified compounds predicted to be stable as atropisomers. After synthesis of the library, analysis showed that compounds <strong>13</strong> and <strong>14</strong> existed as stable atropisomers <strong>13a</strong>, <strong>13b</strong>, <strong>14a</strong> and <strong>14b</strong>, in agreement with the earlier calculations. Screening in a glucocorticoid receptor cellular assay showed that one compound from each atropisomer pair was significantly more potent than the other. Docking in a public structure of the glucocorticoid receptor (PBD code 3E7C) enabled the stereochemistry of the two most potent compounds <strong>13a</strong> and <strong>14b</strong> to be assigned as (<em>R</em><small><sub>a</sub></small>) and (<em>S</em><small><sub>a</sub></small>), respectively.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2357-2371"},"PeriodicalIF":3.597,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141523128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic computational strategies for identifying protein targets and lead discovery 识别蛋白质靶标和发现先导物的系统计算策略
IF 3.597
MedChemComm Pub Date : 2024-05-31 DOI: 10.1039/D4MD00223G
Arti Kataria, Ankit Srivastava, Desh Deepak Singh, Shafiul Haque, Ihn Han and Dharmendra Kumar Yadav
{"title":"Systematic computational strategies for identifying protein targets and lead discovery","authors":"Arti Kataria, Ankit Srivastava, Desh Deepak Singh, Shafiul Haque, Ihn Han and Dharmendra Kumar Yadav","doi":"10.1039/D4MD00223G","DOIUrl":"10.1039/D4MD00223G","url":null,"abstract":"<p >Computational algorithms and tools have retrenched the drug discovery and development timeline. The applicability of computational approaches has gained immense relevance owing to the dramatic surge in the structural information of biomacromolecules and their heteromolecular complexes. Computational methods are now extensively used in identifying new protein targets, druggability assessment, pharmacophore mapping, molecular docking, the virtual screening of lead molecules, bioactivity prediction, molecular dynamics of protein–ligand complexes, affinity prediction, and for designing better ligands. Herein, we provide an overview of salient components of recently reported computational drug-discovery workflows that includes algorithms, tools, and databases for protein target identification and optimized ligand selection.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 2254-2269"},"PeriodicalIF":3.597,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141190500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信